These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 38142460)

  • 1. Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy.
    Maia A; Tarannum M; Romee R
    Stem Cells Transl Med; 2024 Mar; 13(3):230-242. PubMed ID: 38142460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
    Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
    Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.
    McErlean EM; McCarthy HO
    J Nanobiotechnology; 2024 Sep; 22(1):552. PubMed ID: 39256765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Gene Editing Approaches to Fine-Tune the Immune System.
    Pavlovic K; Tristán-Manzano M; Maldonado-Pérez N; Cortijo-Gutierrez M; Sánchez-Hernández S; Justicia-Lirio P; Carmona MD; Herrera C; Martin F; Benabdellah K
    Front Immunol; 2020; 11():570672. PubMed ID: 33117361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
    Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
    Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
    Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
    Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene editing and CRISPR in the clinic: current and future perspectives.
    Hirakawa MP; Krishnakumar R; Timlin JA; Carney JP; Butler KS
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32207531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonviral technologies can pave the way for CAR-NK cell therapy.
    Bexte T; Reindl LM; Ullrich E
    J Leukoc Biol; 2023 Oct; 114(5):475-486. PubMed ID: 37403203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy.
    Mirzaei HR; Pourghadamyari H; Rahmati M; Mohammadi A; Nahand JS; Rezaei A; Mirzaei H; Hadjati J
    Cancer Lett; 2018 Jun; 423():95-104. PubMed ID: 29544719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV.
    Naeimi Kararoudi M; Likhite S; Elmas E; Yamamoto K; Schwartz M; Sorathia K; de Souza Fernandes Pereira M; Sezgin Y; Devine RD; Lyberger JM; Behbehani GK; Chakravarti N; Moriarity BS; Meyer K; Lee DA
    Cell Rep Methods; 2022 Jun; 2(6):100236. PubMed ID: 35784645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.